Download PDF
Clin Colon Rectal Surg
DOI: 10.1055/s-0044-1787825
Review Article

The Ugly: Metastatic Colon Cancer—Surgical Options

Fahima Dossa
1   Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
,
Martin R. Weiser
1   Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Over 50% of patients with colorectal cancer develop metastatic disease. Although systemic therapy remains the backbone of palliative treatment, select patients may be candidates for surgical resection with curative intent. Given increasing evidence of the association between metastasectomy and prolonged survival, surgery has acquired an increasingly central role in the management of liver, lung, and peritoneal metastases. This is compounded by accumulating advances in local and systemic treatments that have allowed for expansion of the resectability pool, bringing the potential for curative surgical treatment to increasing numbers of patients with stage IV disease. However, as the boundaries of resectability are pushed, patient selection and consideration of tumor-related and technical factors are imperative to the identification of patients for whom surgery would be of the greatest benefit.

Keywords

colorectal cancer - metastasis - resection - survival


Publication History

Article published online:
18 June 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Muratore A, Zorzi D, Bouzari H. et al. Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy?. Ann Surg Oncol 2007; 14 (02) 766-770
    CrossrefPubMedGoogle Scholar
  • 2 Hayashi M, Inoue Y, Komeda K. et al. Clinicopathological analysis of recurrence patterns and prognostic factors for survival after hepatectomy for colorectal liver metastasis. BMC Surg 2010; 10: 27
    CrossrefPubMedGoogle Scholar
  • 3 Lee W-S, Yun SH, Chun H-K. et al. Pulmonary resection for metastases from colorectal cancer: prognostic factors and survival. Int J Colorectal Dis 2007; 22 (06) 699-704
    CrossrefPubMedGoogle Scholar
  • 4 Van Cutsem E, Nordlinger B, Adam R. et al; European Colorectal Metastases Treatment Group. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 2006; 42 (14) 2212-2221
    CrossrefPubMedGoogle Scholar
  • 5 Yoo PS, Lopez-Soler RI, Longo WE, Cha CH. Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab. Clin Colorectal Cancer 2006; 6 (03) 202-207
    CrossrefPubMedGoogle Scholar
  • 6 Ferrarotto R, Pathak P, Maru D. et al. Durable complete responses in metastatic colorectal cancer treated with chemotherapy alone. Clin Colorectal Cancer 2011; 10 (03) 178-182
    CrossrefPubMedGoogle Scholar
  • 7 Abdalla EK, Vauthey J-N, Ellis LM. et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004; 239 (06) 818-825 , discussion 825–827
    CrossrefPubMedGoogle Scholar
  • 8 Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 2004; 240 (03) 438-447 , discussion 447–450
    CrossrefPubMedGoogle Scholar
  • 9 de Jong MC, Pulitano C, Ribero D. et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg 2009; 250 (03) 440-448
    CrossrefPubMedGoogle Scholar
  • 10 Wei AC, Greig PD, Grant D, Taylor B, Langer B, Gallinger S. Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol 2006; 13 (05) 668-676
    CrossrefPubMedGoogle Scholar
  • 11 Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230 (03) 309-318 , discussion 318–321
    CrossrefPubMedGoogle Scholar
  • 12 Nordlinger B, Guiguet M, Vaillant JC. et al; Association Française de Chirurgie. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Cancer 1996; 77 (07) 1254-1262
    CrossrefPubMedGoogle Scholar
  • 13 Nagashima I, Takada T, Adachi M, Nagawa H, Muto T, Okinaga K. Proposal of criteria to select candidates with colorectal liver metastases for hepatic resection: comparison of our scoring system to the positive number of risk factors. World J Gastroenterol 2006; 12 (39) 6305-6309
    CrossrefPubMedGoogle Scholar
  • 14 Konopke R, Kersting S, Distler M. et al. Prognostic factors and evaluation of a clinical score for predicting survival after resection of colorectal liver metastases. Liver Int 2009; 29 (01) 89-102
    CrossrefPubMedGoogle Scholar
  • 15 Amikura K, Akagi K, Ogura T, Takahashi A, Sakamoto H. The RAS mutation status predicts survival in patients undergoing hepatic resection for colorectal liver metastases: the results from a genetic analysis of all-RAS. J Surg Oncol 2018; 117 (04) 745-755
    CrossrefPubMedGoogle Scholar
  • 16 Passot G, Kim BJ, Glehen O. et al; BIG-RENAPE Working Group. Impact of RAS mutations in metastatic colorectal cancer after potentially curative resection: does site of metastases matter?. Ann Surg Oncol 2018; 25 (01) 179-187
    CrossrefPubMedGoogle Scholar
  • 17 Vauthey J-N, Zimmitti G, Kopetz SE. et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg 2013; 258 (04) 619-626 , discussion 626–627
    CrossrefPubMedGoogle Scholar
  • 18 Brudvik KW, Jones RP, Giuliante F. et al. RAS mutation clinical risk score to predict survival after resection of colorectal liver metastases. Ann Surg 2019; 269 (01) 120-126
    CrossrefPubMedGoogle Scholar
  • 19 Brudvik KW, Mise Y, Chung MH. et al. RAS mutation predicts positive resection margins and narrower resection margins in patients undergoing resection of colorectal liver metastases. Ann Surg Oncol 2016; 23 (08) 2635-2643
    CrossrefPubMedGoogle Scholar
  • 20 Margonis GA, Buettner S, Andreatos N. et al. Anatomical resections improve disease-free survival in patients with KRAS-mutated colorectal liver metastases. Ann Surg 2017; 266 (04) 641-649
    CrossrefPubMedGoogle Scholar
  • 21 Margonis GA, Sasaki K, Andreatos N. et al. KRAS mutation status dictates optimal surgical margin width in patients undergoing resection of colorectal liver metastases. Ann Surg Oncol 2017; 24 (01) 264-271
    CrossrefPubMedGoogle Scholar
  • 22 Margonis GA, Buettner S, Andreatos N. et al. Association of BRAF mutations with survival and recurrence in surgically treated patients with metastatic colorectal liver cancer. JAMA Surg 2018; 153 (07) e180996-e180996
    CrossrefPubMedGoogle Scholar
  • 23 Gagnière J, Dupré A, Gholami SS. et al. Is hepatectomy justified for BRAF mutant colorectal liver metastases? A multi-institutional analysis of 1497 patients. Ann Surg 2020; 271 (01) 147-154
    CrossrefPubMedGoogle Scholar
  • 24 Blazer III DG, Kishi Y, Maru DM. et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 2008; 26 (33) 5344-5351
    CrossrefPubMedGoogle Scholar
  • 25 Adam R, Delvart V, Pascal G. et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004; 240 (04) 644-657 , discussion 657–658
    CrossrefPubMedGoogle Scholar
  • 26 Creasy JM, Sadot E, Koerkamp BG. et al. The impact of primary tumor location on long-term survival in patients undergoing hepatic resection for metastatic colon cancer. Ann Surg Oncol 2018; 25 (02) 431-438
    CrossrefPubMedGoogle Scholar
  • 27 Yamashita S, Brudvik KW, Kopetz SE. et al. Embryonic origin of primary colon cancer predicts pathologic response and survival in patients undergoing resection for colon cancer liver metastases. Ann Surg 2018; 267 (03) 514-520
    CrossrefPubMedGoogle Scholar
  • 28 Charnsangavej C, Clary B, Fong Y, Grothey A, Pawlik TM, Choti MA. Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 2006; 13 (10) 1261-1268
    CrossrefPubMedGoogle Scholar
  • 29 Deng G, Li H, Jia GQ. et al. Parenchymal-sparing versus extended hepatectomy for colorectal liver metastases: a systematic review and meta-analysis. Cancer Med 2019; 8 (14) 6165-6175
    CrossrefPubMedGoogle Scholar
  • 30 Moris D, Ronnekleiv-Kelly S, Rahnemai-Azar AA. et al. Parenchymal-sparing versus anatomic liver resection for colorectal liver metastases: a systematic review. J Gastrointest Surg 2017; 21 (06) 1076-1085
    CrossrefPubMedGoogle Scholar
  • 31 Boudjema K, Locher C, Sabbagh C. et al. Simultaneous versus delayed resection for initially resectable synchronous colorectal cancer liver metastases: a prospective, open-label, randomized, controlled trial. Ann Surg 2021; 273 (01) 49-56
    CrossrefPubMedGoogle Scholar
  • 32 Tang W, Ren L, Liu T. et al. Bevacizumab plus mFOLFOX6 versus mFOLFOX6 alone as first-line treatment for RAS mutant unresectable colorectal liver-limited metastases: the BECOME randomized controlled trial. J Clin Oncol 2020; 38 (27) 3175-3184
    CrossrefPubMedGoogle Scholar
  • 33 Folprecht G, Gruenberger T, Bechstein WO. et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010; 11 (01) 38-47
    CrossrefPubMedGoogle Scholar
  • 34 Adam R, Aloia T, Lévi F. et al. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol 2007; 25 (29) 4593-4602
    CrossrefPubMedGoogle Scholar
  • 35 Pak LM, Kemeny NE, Capanu M. et al. Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: long term results and curative potential. J Surg Oncol 2018; 117 (04) 634-643
    CrossrefPubMedGoogle Scholar
  • 36 Wicherts DA, Miller R, de Haas RJ. et al. Long-term results of two-stage hepatectomy for irresectable colorectal cancer liver metastases. Ann Surg 2008; 248 (06) 994-1005
    CrossrefPubMedGoogle Scholar
  • 37 Jaeck D, Oussoultzoglou E, Rosso E, Greget M, Weber J-C, Bachellier P. A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases. Ann Surg 2004; 240 (06) 1037-1049 , discussion 1049–1051
    CrossrefPubMedGoogle Scholar
  • 38 Narita M, Oussoultzoglou E, Jaeck D. et al. Two-stage hepatectomy for multiple bilobar colorectal liver metastases. Br J Surg 2011; 98 (10) 1463-1475
    CrossrefPubMedGoogle Scholar
  • 39 Brouquet A, Abdalla EK, Kopetz S. et al. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol 2011; 29 (08) 1083-1090
    CrossrefPubMedGoogle Scholar
  • 40 Tsai S, Marques HP, de Jong MC. et al. Two-stage strategy for patients with extensive bilateral colorectal liver metastases. HPB (Oxford) 2010; 12 (04) 262-269
    CrossrefPubMedGoogle Scholar
  • 41 Schnitzbauer AA, Lang SA, Goessmann H. et al. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg 2012; 255 (03) 405-414
    CrossrefPubMedGoogle Scholar
  • 42 Aloia TA, Vauthey J-N. Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS): what is gained and what is lost?. Ann Surg 2012; 256 (03) e9 , author reply e16–e19
    CrossrefPubMedGoogle Scholar
  • 43 Dokmak S, Belghiti J. Which limits to the “ALPPS” approach?. Ann Surg 2012; 256 (03) e6 , author reply e16–e17
    CrossrefPubMedGoogle Scholar
  • 44 Sandström P, Røsok BI, Sparrelid E. et al. ALPPS improves resectability compared with conventional two-stage hepatectomy in patients with advanced colorectal liver metastasis: results from a Scandinavian multicenter randomized controlled trial (LIGRO trial). Ann Surg 2018; 267 (05) 833-840
    CrossrefPubMedGoogle Scholar
  • 45 Hasselgren K, Røsok BI, Larsen PN. et al. ALPPS improves survival compared with TSH in patients affected of CRLM: survival analysis from the randomized controlled trial LIGRO. Ann Surg 2021; 273 (03) 442-448
    CrossrefPubMedGoogle Scholar
  • 46 Viganò L, Capussotti L, Lapointe R. et al. Early recurrence after liver resection for colorectal metastases: risk factors, prognosis, and treatment. a LiverMetSurvey-based study of 6,025 patients. Ann Surg Oncol 2014; 21 (04) 1276-1286
    CrossrefPubMedGoogle Scholar
  • 47 Denbo JW, Yamashita S, Passot G. et al. RAS mutation is associated with decreased survival in patients undergoing repeat hepatectomy for colorectal liver metastases. J Gastrointest Surg 2017; 21 (01) 68-77
    CrossrefPubMedGoogle Scholar
  • 48 Andreou A, Brouquet A, Abdalla EK, Aloia TA, Curley SA, Vauthey JN. Repeat hepatectomy for recurrent colorectal liver metastases is associated with a high survival rate. HPB (Oxford) 2011; 13 (11) 774-782
    CrossrefPubMedGoogle Scholar
  • 49 Adam R, Bismuth H, Castaing D. et al. Repeat hepatectomy for colorectal liver metastases. Ann Surg 1997; 225 (01) 51-60 , discussion 60–62
    CrossrefPubMedGoogle Scholar
  • 50 Nordlinger B, Vaillant JC, Guiguet M. et al; Association Francaise de Chirurgie. Survival benefit of repeat liver resections for recurrent colorectal metastases: 143 cases. J Clin Oncol 1994; 12 (07) 1491-1496
    CrossrefPubMedGoogle Scholar
  • 51 Ishiguro S, Akasu T, Fujimoto Y. et al. Second hepatectomy for recurrent colorectal liver metastasis: analysis of preoperative prognostic factors. Ann Surg Oncol 2006; 13 (12) 1579-1587
    CrossrefPubMedGoogle Scholar
  • 52 Tanaka K, Shimada H, Ohta M. et al. Procedures of choice for resection of primary and recurrent liver metastases from colorectal cancer. World J Surg 2004; 28 (05) 482-487
    CrossrefPubMedGoogle Scholar
  • 53 Wicherts DA, de Haas RJ, Salloum C. et al. Repeat hepatectomy for recurrent colorectal metastases. Br J Surg 2013; 100 (06) 808-818
    CrossrefPubMedGoogle Scholar
  • 54 Neal CP, Nana GR, Jones M. et al. Repeat hepatectomy is independently associated with favorable long-term outcome in patients with colorectal liver metastases. Cancer Med 2017; 6 (02) 331-338
    CrossrefPubMedGoogle Scholar
  • 55 Hagness M, Foss A, Line P-D. et al. Liver transplantation for nonresectable liver metastases from colorectal cancer. Ann Surg 2013; 257 (05) 800-806
    CrossrefPubMedGoogle Scholar
  • 56 Dueland S, Syversveen T, Solheim JM. et al. Survival following liver transplantation for patients with nonresectable liver-only colorectal metastases. Ann Surg 2020; 271 (02) 212-218
    CrossrefPubMedGoogle Scholar
  • 57 Qiu M, Hu J, Yang D, Cosgrove D, Xu R. Pattern of distant metastases in colorectal cancer: a SEER based study. Oncotarget 2015; 6 (36) 38658-38666
    CrossrefPubMedGoogle Scholar
  • 58 Mitry E, Guiu B, Cosconea S, Jooste V, Faivre J, Bouvier A-M. Epidemiology, management and prognosis of colorectal cancer with lung metastases: a 30-year population-based study. Gut 2010; 59 (10) 1383-1388
    CrossrefPubMedGoogle Scholar
  • 59 Pastorino U, Buyse M, Friedel G. et al; International Registry of Lung Metastases. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg 1997; 113 (01) 37-49
    CrossrefPubMedGoogle Scholar
  • 60 Hornbech K, Ravn J, Steinbrüchel DA. Outcome after pulmonary metastasectomy: analysis of 5 years consecutive surgical resections 2002-2006. J Thorac Oncol 2011; 6 (10) 1733-1740
    CrossrefPubMedGoogle Scholar
  • 61 Dudek W, Schreiner W, Haj Khalaf M, Sirbu H. Surgery for pulmonary metastases: long-term survival in 281 patients. Thorac Cardiovasc Surg 2021; 69 (07) 660-665
    Article in Thieme ConnectPubMedGoogle Scholar
  • 62 Suzuki H, Kiyoshima M, Kitahara M, Asato Y, Amemiya R. Long-term outcomes after surgical resection of pulmonary metastases from colorectal cancer. Ann Thorac Surg 2015; 99 (02) 435-440
    CrossrefPubMedGoogle Scholar
  • 63 Booth CM, Nanji S, Wei X, Mackillop WJ. Outcomes of resected colorectal cancer lung metastases in routine clinical practice: a population-based study. Ann Surg Oncol 2016; 23 (04) 1057-1063
    CrossrefPubMedGoogle Scholar
  • 64 Okumura T, Boku N, Hishida T. et al. Surgical outcome and prognostic stratification for pulmonary metastasis from colorectal cancer. Ann Thorac Surg 2017; 104 (03) 979-987
    CrossrefPubMedGoogle Scholar
  • 65 Treasure T, Farewell V, Macbeth F. et al; PulMiCCinvestigators. The pulmonary metastasectomy in colorectal cancer cohort study: analysis of case selection, risk factors and survival in a prospective observational study of 512 patients. Colorectal Dis 2021; 23 (07) 1793-1803
    CrossrefPubMedGoogle Scholar
  • 66 Milosevic M, Edwards J, Tsang D. et al. Pulmonary metastasectomy in colorectal cancer: updated analysis of 93 randomized patients - control survival is much better than previously assumed. Colorectal Dis 2020; 22 (10) 1314-1324
    CrossrefPubMedGoogle Scholar
  • 67 Treasure T, Farewell V, Macbeth F. et al; PulMiCC Trial Group. Pulmonary metastasectomy versus continued active monitoring in colorectal cancer (PulMiCC): a multicentre randomised clinical trial. Trials 2019; 20 (01) 718
    CrossrefPubMedGoogle Scholar
  • 68 Vogel JD, Felder SI, Bhama AR. et al. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of colon cancer. Dis Colon Rectum 2022; 65 (02) 148-177
    CrossrefPubMedGoogle Scholar
  • 69 Handy JR, Bremner RM, Crocenzi TS. et al. Expert consensus document on pulmonary metastasectomy. Ann Thorac Surg 2019; 107 (02) 631-649
    CrossrefPubMedGoogle Scholar
  • 70 Benson AB, Venook AP, Al-Hawary MM. et al. Colon cancer, version 1.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2021; 19 (03) 329-359
    CrossrefPubMedGoogle Scholar
  • 71 Gonzalez M, Poncet A, Combescure C, Robert J, Ris HB, Gervaz P. Risk factors for survival after lung metastasectomy in colorectal cancer patients: a systematic review and meta-analysis. Ann Surg Oncol 2013; 20 (02) 572-579
    CrossrefPubMedGoogle Scholar
  • 72 Iida T, Nomori H, Shiba M. et al; Metastatic Lung Tumor Study Group of Japan. Prognostic factors after pulmonary metastasectomy for colorectal cancer and rationale for determining surgical indications: a retrospective analysis. Ann Surg 2013; 257 (06) 1059-1064
    CrossrefPubMedGoogle Scholar
  • 73 Iizasa T, Suzuki M, Yoshida S. et al. Prediction of prognosis and surgical indications for pulmonary metastasectomy from colorectal cancer. Ann Thorac Surg 2006; 82 (01) 254-260
    CrossrefPubMedGoogle Scholar
  • 74 Koga R, Yamamoto J, Saiura A, Yamaguchi T, Hata E, Sakamoto M. Surgical resection of pulmonary metastases from colorectal cancer: four favourable prognostic factors. Jpn J Clin Oncol 2006; 36 (10) 643-648
    CrossrefPubMedGoogle Scholar
  • 75 Monteiro A, Arce N, Bernardo J, Eugénio L, Antunes MJ. Surgical resection of lung metastases from epithelial tumors. Ann Thorac Surg 2004; 77 (02) 431-437
    CrossrefPubMedGoogle Scholar
  • 76 Rama N, Monteiro A, Bernardo JE, Eugénio L, Antunes MJ. Lung metastases from colorectal cancer: surgical resection and prognostic factors. Eur J Cardiothorac Surg 2009; 35 (03) 444-449
    CrossrefPubMedGoogle Scholar
  • 77 Zampino MG, Maisonneuve P, Ravenda PS. et al. Lung metastases from colorectal cancer: analysis of prognostic factors in a single institution study. Ann Thorac Surg 2014; 98 (04) 1238-1245
    CrossrefPubMedGoogle Scholar
  • 78 Embun R, Rivas de Andrés JJ, Call S. et al; Spanish Group of Lung Metastases of Colo-Rectal Cancer (GECMP-CCR) of the Spanish Society of Pneumology and Thoracic Surgery (SEPAR). Causal model of survival after pulmonary metastasectomy of colorectal cancer: a nationwide prospective registry. Ann Thorac Surg 2016; 101 (05) 1883-1890
    CrossrefPubMedGoogle Scholar
  • 79 Saito Y, Omiya H, Kohno K. et al. Pulmonary metastasectomy for 165 patients with colorectal carcinoma: a prognostic assessment. J Thorac Cardiovasc Surg 2002; 124 (05) 1007-1013
    CrossrefPubMedGoogle Scholar
  • 80 Watanabe K, Nagai K, Kobayashi A, Sugito M, Saito N. Factors influencing survival after complete resection of pulmonary metastases from colorectal cancer. Br J Surg 2009; 96 (09) 1058-1065
    CrossrefPubMedGoogle Scholar
  • 81 Welter S, Jacobs J, Krbek T, Poettgen C, Stamatis G. Prognostic impact of lymph node involvement in pulmonary metastases from colorectal cancer. Eur J Cardiothorac Surg 2007; 31 (02) 167-172
    CrossrefPubMedGoogle Scholar
  • 82 Onaitis MW, Petersen RP, Haney JC. et al. Prognostic factors for recurrence after pulmonary resection of colorectal cancer metastases. Ann Thorac Surg 2009; 87 (06) 1684-1688
    CrossrefPubMedGoogle Scholar
  • 83 Corsini EM, Mitchell KG, Correa A, Morris VK, Antonoff MB. MD Anderson Pulmonary Metastasectomy Working Group. Effect of primary colorectal cancer tumor location on survival after pulmonary metastasectomy. J Thorac Cardiovasc Surg 2021; 162 (01) 296-305
    CrossrefPubMedGoogle Scholar
  • 84 Corsini EM, Mitchell KG, Mehran RJ. et al. Colorectal cancer mutations are associated with survival and recurrence after pulmonary metastasectomy. J Surg Oncol 2019; 120 (04) 729-735
    CrossrefPubMedGoogle Scholar
  • 85 Tanaka Y, Maniwa Y, Nishio W, Yoshimura M, Okita Y. The optimal timing to resect pulmonary metastasis. Eur J Cardiothorac Surg 2008; 33 (06) 1135-1138
    CrossrefPubMedGoogle Scholar
  • 86 Patel NA, Keenan RJ, Medich DS. et al. The presence of colorectal hepatic metastases does not preclude pulmonary metastasectomy. Am Surg 2003; 69 (12) 1047-1053 , discussion 1053
    CrossrefPubMedGoogle Scholar
  • 87 Mise Y, Imamura H, Hashimoto T. et al. Cohort study of the survival benefit of resection for recurrent hepatic and/or pulmonary metastases after primary hepatectomy for colorectal metastases. Ann Surg 2010; 251 (05) 902-909
    CrossrefPubMedGoogle Scholar
  • 88 Hishida T, Tsuboi M, Okumura T. et al. Does repeated lung resection provide long-term survival for recurrent pulmonary metastases of colorectal cancer? Results of a retrospective Japanese multicenter study. Ann Thorac Surg 2017; 103 (02) 399-405
    CrossrefPubMedGoogle Scholar
  • 89 Jaklitsch MT, Mery CM, Lukanich JM. et al. Sequential thoracic metastasectomy prolongs survival by re-establishing local control within the chest. J Thorac Cardiovasc Surg 2001; 121 (04) 657-667
    CrossrefPubMedGoogle Scholar
  • 90 Kanzaki R, Higashiyama M, Oda K. et al. Outcome of surgical resection for recurrent pulmonary metastasis from colorectal carcinoma. Am J Surg 2011; 202 (04) 419-426
    CrossrefPubMedGoogle Scholar
  • 91 Ambrogi V, Tamburrini A, Tajé R. Results of redo pulmonary metastasectomy. J Thorac Dis 2021; 13 (04) 2669-2685
    CrossrefPubMedGoogle Scholar
  • 92 Segelman J, Granath F, Holm T, Machado M, Mahteme H, Martling A. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg 2012; 99 (05) 699-705
    CrossrefPubMedGoogle Scholar
  • 93 Hompes D, D'Hoore A, Van Cutsem E. et al. The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study. Ann Surg Oncol 2012; 19 (07) 2186-2194
    CrossrefPubMedGoogle Scholar
  • 94 Leung V, Huo YR, Liauw W, Morris DL. Oxaliplatin versus mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis. Eur J Surg Oncol 2017; 43 (01) 144-149
    CrossrefPubMedGoogle Scholar
  • 95 Franko J, Shi Q, Goldman CD. et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol 2012; 30 (03) 263-267
    CrossrefPubMedGoogle Scholar
  • 96 Jayakrishnan TT, Zacharias AJ, Sharma A, Pappas SG, Gamblin TC, Turaga KK. Role of laparoscopy in patients with peritoneal metastases considered for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). World J Surg Oncol 2014; 12 (01) 270
    CrossrefPubMedGoogle Scholar
  • 97 Elias D, Mariani A, Cloutier A-S. et al. Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin. Eur J Surg Oncol 2014; 40 (11) 1467-1473
    CrossrefPubMedGoogle Scholar
  • 98 Elias D, Lefevre JH, Chevalier J. et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 2009; 27 (05) 681-685
    CrossrefPubMedGoogle Scholar
  • 99 Goéré D, Sourrouille I, Gelli M, Benhaim L, Faron M, Honoré C. Peritoneal metastases from colorectal cancer: treatment principles and perspectives. Surg Oncol Clin N Am 2018; 27 (03) 563-583
    CrossrefPubMedGoogle Scholar
  • 100 Group CCW. Chicago Consensus Working Group. The Chicago consensus on peritoneal surface malignancies: management of colorectal metastases. Ann Surg Oncol 2020; 27 (06) 1761-1767
    CrossrefPubMedGoogle Scholar
  • 101 Cao CQ, Yan TD, Liauw W, Morris DL. Comparison of optimally resected hepatectomy and peritonectomy patients with colorectal cancer metastasis. J Surg Oncol 2009; 100 (07) 529-533
    CrossrefPubMedGoogle Scholar
  • 102 Shen P, Thai K, Stewart JH. et al. Peritoneal surface disease from colorectal cancer: comparison with the hepatic metastases surgical paradigm in optimally resected patients. Ann Surg Oncol 2008; 15 (12) 3422-3432
    CrossrefPubMedGoogle Scholar
  • 103 Morris VK, Kennedy EB, Baxter NN. et al. Treatment of metastatic colorectal cancer: ASCO guideline. J Clin Oncol 2023; 41 (03) 678-700
    CrossrefPubMedGoogle Scholar
  • 104 Sugarbaker PH, Schellinx ME, Chang D, Koslowe P, von Meyerfeldt M. Peritoneal carcinomatosis from adenocarcinoma of the colon. World J Surg 1996; 20 (05) 585-591 , discussion 592
    CrossrefPubMedGoogle Scholar
  • 105 Verwaal VJ, van Ruth S, de Bree E. et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003; 21 (20) 3737-3743
    CrossrefPubMedGoogle Scholar
  • 106 Cashin PH, Mahteme H, Spång N. et al. Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: a randomised trial. Eur J Cancer 2016; 53: 155-162
    CrossrefPubMedGoogle Scholar
  • 107 Elias D, Delperro J-R, Sideris L. et al. Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting randomized trials. Ann Surg Oncol 2004; 11 (05) 518-521
    CrossrefPubMedGoogle Scholar
  • 108 Quénet F, Elias D, Roca L. et al; UNICANCER-GI Group and BIG Renape Group. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22 (02) 256-266
    CrossrefPubMedGoogle Scholar
  • 109 Kanemitsu Y, Shitara K, Mizusawa J. et al; JCOG Colorectal Cancer Study Group. Primary tumor resection plus chemotherapy versus chemotherapy alone for colorectal cancer patients with asymptomatic, synchronous unresectable metastases (JCOG1007; iPACS): a randomized clinical trial. J Clin Oncol 2021; 39 (10) 1098-1107
    CrossrefPubMedGoogle Scholar
  • 110 van der Kruijssen DEW, Elias SG, Vink GR. et al; CAIRO4 Working Group. Sixty-day mortality of patients with metastatic colorectal cancer randomized to systemic treatment vs primary tumor resection followed by systemic treatment: the CAIRO4 phase 3 randomized clinical trial. JAMA Surg 2021; 156 (12) 1093-1101
    CrossrefPubMedGoogle Scholar
  • 111 Poultsides GA, Servais EL, Saltz LB. et al. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol 2009; 27 (20) 3379-3384
    CrossrefPubMedGoogle Scholar
  • 112 McCahill LE, Yothers G, Sharif S. et al. Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10. J Clin Oncol 2012; 30 (26) 3223-3228
    CrossrefPubMedGoogle Scholar
  • 113 Baxter NN, Sutradhar R, Dossa F. et al. Does the presence of an intact primary increase the risk of nonelective colorectal surgery in patients treated with bevacizumab?. Colorectal Dis 2020; 22 (12) 1974-1983
    CrossrefPubMedGoogle Scholar
  • 114 Van Cutsem E, Rivera F, Berry S. et al; First BEAT investigators. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009; 20 (11) 1842-1847
    CrossrefPubMedGoogle Scholar
  • 115 Kozloff M, Yood MU, Berlin J. et al; Investigators of the BRiTE study. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist 2009; 14 (09) 862-870
    CrossrefPubMedGoogle Scholar
  • 116 Bong JW, Lee JL, Kim CW. et al. Risk factors and adequate management for complications of bevacizumab treatment requiring surgical intervention in patients with metastatic colorectal cancer. Clin Colorectal Cancer 2018; 17 (04) e639-e645
    CrossrefPubMedGoogle Scholar